Advertisement

Topics

Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies

11:39 EDT 13 Sep 2018 | Speciality Pharma Journal

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. The total transaction value of …

Original Article: Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...